RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000077.xml
PDF herunterladen
Semin Thromb Hemost 2015; 41(05): 468-473
DOI: 10.1055/s-0035-1550430
DOI: 10.1055/s-0035-1550430
Rebalanced Hemostasis in Patients with Acute Liver Failure
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
06. Juni 2015 (online)
Abstract
Patients with acute liver failure (ALF) have substantial alterations in their hemostatic system. Since an international normalized ratio of ≥ 1.5 is part of the definition of the syndrome, it has long been believed that patients with ALF had a hemostasis-related bleeding tendency. Recent data, however, show that spontaneous bleeding in ALF is rare. In addition, thrombotic complications may be more common than spontaneous bleeding complications. Laboratory studies have suggested that patients with ALF may be in hemostatic balance as a result of a commensurate decline in pro- and anti-hemostatic factors. The unstable nature of the hemostatic balance in ALF may explain the occurrence of both bleeding and thrombotic complications. The hemostatic profile of patients with ALF includes hypercoagulable features, including von Willebrand factor/a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 unbalance, elevated levels of highly procoagulant, platelet-derived microparticles, and a profound hypofibrinolytic status. These hypercoagulable features may contribute to systemic thrombotic complications, but may also drive intrahepatic clot formation. Studies in experimental animal models of ALF have demonstrated that intrahepatic clot formation contributes to disease progression. The clinical consequences of these new insights in the hemostatic system of patients with ALF will be discussed in this review.
-
References
- 1 Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 37 (2) 280-287
- 2 Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. Systematic review: acute liver failure - one disease, more than 40 definitions. Aliment PharmacolTher 2012; 35 (11) 1245-1256
- 3 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116 (6) 878-885
- 4 Pereira LM, Langley PG, Hayllar KM, Tredger JM, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut 1992; 33 (1) 98-102
- 5 Izumi S, Langley PG, Wendon J , et al. Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure. Hepatology 1996; 23 (6) 1507-1511
- 6 Gazzard BG, Henderson JM, Williams R. Factor VII levels as a guide to prognosis in fulminant hepatic failure. Gut 1976; 17 (7) 489-491
- 7 Bernuau J, Goudeau A, Poynard T , et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6 (4) 648-651
- 8 Kerr R, Newsome P, Germain L , et al. Effects of acute liver injury on blood coagulation. J ThrombHaemost 2003; 1 (4) 754-759
- 9 Stravitz RT, Lisman T, Luketic VA , et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56 (1) 129-136
- 10 Habib M, Roberts LN, Patel RK, Wendon J, Bernal W, Arya R. Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. Liver Int 2014; 34 (5) 672-678
- 11 Agarwal B, Wright G, Gatt A , et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57 (4) 780-786
- 12 Potze W, Arshad F, Adelmeijer J , et al. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. Br J Haematol 2013; 162 (6) 819-826
- 13 Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J ThrombHaemost 2012; 10 (7) 1312-1319
- 14 Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. J Hepatol 2011; 55 (6) 1415-1427
- 15 Rubin MH, Weston MJ, Bullock G , et al. Abnormal platelet function and ultrastructure in fulminant hepatic failure. Q J Med 1977; 46 (183) 339-352
- 16 Weston MJ, Langley PG, Rubin MH, Hanid MA, Mellon P, Williams R. Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 1977; 18 (11) 897-902
- 17 Stravitz RT, Bowling R, Bradford RL , et al. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology 2013; 58 (1) 304-313
- 18 Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013; 58 (2) 752-761
- 19 Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000; 98 (4) 323-332
- 20 Chen J, Reheman A, Gushiken FC , et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121 (2) 593-603
- 21 Hillenbrand P, Parbhoo SP, Jedrychowski A, Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 1974; 15 (2) 83-88
- 22 Ganey PE, Luyendyk JP, Newport SW , et al. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 2007; 46 (4) 1177-1186
- 23 Weerasinghe SV, Moons DS, Altshuler PJ, Shah YM, Omary MB. Fibrinogen-γ proteolysis and solubility dynamics during apoptotic mouse liver injury: heparin prevents and treats liver damage. Hepatology 2011; 53 (4) 1323-1332
- 24 Sullivan BP, Kopec AK, Joshi N , et al. Hepatocyte tissue factor activates the coagulation cascade in mice. Blood 2013; 121 (10) 1868-1874
- 25 Levy GA, Liu M, Ding J , et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000; 156 (4) 1217-1225
- 26 Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32 (4 Pt 1) 734-739
- 27 Hollestelle MJ, Poyck PP, Hollestelle JM, Marsman HA, Mourik JA, Gulik TM. Extra-hepatic factor VIII expression in porcine fulminant hepatic failure. J ThrombHaemost 2005; 3 (10) 2274-2280
- 28 Tuddenham E. In search of the source of factor VIII. Blood 2014; 123 (24) 3691
- 29 Shahani T, Covens K, Lavend'homme R , et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J ThrombHaemost 2014; 12 (1) 36-42
- 30 Schiødt FV, Balko J, Schilsky M, Harrison ME, Thornton A, Lee WM ; Acute Liver Failure Study Group. Thrombopoietin in acute liver failure. Hepatology 2003; 37 (3) 558-561
- 31 Peck-Radosavljevic M, Wichlas M, Zacherl J , et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95 (3) 795-801
- 32 Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lee WM. Thrombocytopenia in acute liver failure (ALF): a marker of multi-organ system failure and poor prognosis. Hepatology 2013; 58 (S1) 262A
- 33 Clark R, Rake MO, Flute PT, Williams R. Coagulation abnormalities in acute liver failure; pathogenetic and therapeutic implications. Scand J GastroenterolSuppl 1973; 19 (8) 63-70
- 34 Gazzard BG, Portmann B, Murray-Lyon IM, Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q J Med 1975; 44 (176) 615-626
- 35 Stravitz RT, Ellerbe C, Durkalski V, Schilski ML, Lee WM. Spontaneous bleeding complications in acute liver failure (ALF). Hepatology 2013; 58 (S1) 347A
- 36 Vaquero J, Fontana RJ, Larson AM , et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 11 (12) 1581-1589
- 37 Shida Y, Nishio K, Sugimoto M , et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 2008; 111 (3) 1295-1298
- 38 Lisman T, Leebeek FW, Mosnier LO , et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121 (1) 131-139
- 39 Lisman T, Bongers TN, Adelmeijer J , et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (1) 53-61
- 40 Tripodi A, Salerno F, Chantarangkul V , et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (3) 553-558
- 41 Munoz SJ, Rajender Reddy K, Lee W ; Acute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008; 9 (1) 103-107
- 42 Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment PharmacolTher 2007; 26 (2) 141-148
- 43 Castaldo ET, Chari RS. Liver transplantation for acute hepatic failure. HPB (Oxford) 2006; 8 (1) 29-34
- 44 Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis 2009; 13 (1) 95-107
- 45 Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 112 (7) 2617-2626
- 46 Benson AB, Austin GL, Berg M , et al. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med 2010; 36 (10) 1710-1717
- 47 Massicotte L, Beaulieu D, Thibeault L , et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation 2008; 85 (7) 956-962
- 48 Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. GastroenterolHepatol (N Y) 2012; 8 (8) 513-520
- 49 Kirchner C, Dirkmann D, Treckmann JW , et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54 (10 Pt 2) 2760-2768
- 50 Pavese P, Bonadona A, Beaubien J , et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005; 52 (1) 26-29
- 51 Villa E, Cammà C, Marietta M , et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (5) 1253-60.e1 , 4
- 52 Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009; 13 (1) 117-126
- 53 Gazzard BG, Clark R, Borirakchanyavat V, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 1974; 15 (2) 89-93